Excellent summary. Especially good to hear that CZD's technology has several advantages over current widely used techniques.
'Showing that the NovoSorb biodegradable material can be successfully incorporated into a wound for treatment is a major advance for Calzada. Greenwood suggested the technology is very close to entering a paradigm shift in the field of wound treatment. With the results achieved this year, we expect this stock will start to receive increased attention from investors.'
Very odd that the SP has not reflected this significant advance ?
- Forums
- ASX - By Stock
- CZD
- bioshares report
bioshares report
-
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NVA
Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter
IGO
IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity